A new
More about the ADC facility
The planned greenfield facility will be the company's first end-to-end ADC production site”
The planned greenfield facility will be the company's first end-to-end antibody drug conjugate production site.
All steps of the manufacturing process at a commercial scale will be incorporated. This includes antibody production, chemotherapy drug and linker synthesis, conjugating the drug-linker to the antibody, as well as filling of the completed ADC substance,
“We welcome AstraZeneca’s decision to establish a manufacturing presence in
The pharmaceutical firm stated that it is planning to begin the design and construction of the manufacturing facility by the end of 2024. It is anticipated that operations will be ready to commence from 2029.
Biologics market
According to Sigma Mostafa, PhD, Chief Scientific Officer at the contract development and manufacturing organisation (CDMO)
She explained that an exciting development in the sector over the past several years is "the diversification of the biologics structures we are seeing in the pipeline of most major pharma and biotech companies. There are a lot of conjugated products in the clinical pipeline and novel conjugation partners and chemistries are being tried".
The post
© Russell Publishing Limited, 2024. All Rights Reserved., source